Pharmacoeconomic review report : Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue pharma)

Pharmacoeconomic review report Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue pharma)

Netupitant/palonosetron (Akynzeo) is an oral fixed-dose combination of netupitant, a neurokinin-1 (NK1) receptor antagonist (RA), and palonosetron, a 5-hydroxytryptamine-3 (5-HT3) RA, available as a 300 mg/0.5 mg oral capsule. In combination with dexamethasone, netupitant/palonosetron (NEPA) is indi...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : CADTH 2018.
Colección:Common drug review clinical review report.
Materias:
Antiemetics.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269006719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's Pharmacoeconomic Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Issues for Consideration
  • Patient Input
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Summary of Key Outcomes
  • Appendix 3. Additional Information
  • Appendix 4. Summary of Other Health Technology Assessment Reviews of Drug
  • Appendix 5. Reviewer Worksheets
  • References.

Ejemplares similares